Identification of disulfidptosis-related subgroups and prognostic signatures in lung adenocarcinoma using machine learning and experimental validation

被引:5
|
作者
Wang, Yuzhi [1 ]
Xu, Yunfei [2 ]
Liu, Chunyang [3 ]
Yuan, Chengliang [1 ]
Zhang, Yi [4 ]
机构
[1] Deyang Peoples Hosp, Dept Lab Med, Deyang, Sichuan, Peoples R China
[2] Chengdu Womens & Childrens Cent Hosp, Dept Lab Med, Chengdu, Sichuan, Peoples R China
[3] First Peoples Hosp Yibin, Dept Ultrasound, Yibin, Sichuan, Peoples R China
[4] Deyang Peoples Hosp, Dept Blood Transfus, Deyang, Sichuan, Peoples R China
来源
FRONTIERS IN IMMUNOLOGY | 2023年 / 14卷
关键词
disulfidptosis; lung adenocarcinoma; prognosis; tumor microenvironment; immunotherapy; T-CELL; INDOLEAMINE 2,3-DIOXYGENASE; INFILTRATING IMMUNE; R PACKAGE; CANCER; PROLIFERATION; GLIOBLASTOMA; CHEMOTHERAPY; GEMCITABINE; RESISTANCE;
D O I
10.3389/fimmu.2023.1233260
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
BackgroundDisulfidptosis is a newly identified variant of cell death characterized by disulfide accumulation, which is independent of ATP depletion. Accordingly, the latent influence of disulfidptosis on the prognosis of lung adenocarcinoma (LUAD) patients and the progression of tumors remains poorly understood.MethodsWe conducted a multifaceted analysis of the transcriptional and genetic modifications in disulfidptosis regulators (DRs) specific to LUAD, followed by an evaluation of their expression configurations to define DR clusters. Harnessing the differentially expressed genes (DEGs) identified from these clusters, we formulated an optimal predictive model by amalgamating 10 distinct machine learning algorithms across 101 unique combinations to compute the disulfidptosis score (DS). Patients were subsequently stratified into high and low DS cohorts based on median DS values. We then performed an exhaustive comparison between these cohorts, focusing on somatic mutations, clinical attributes, tumor microenvironment, and treatment responsiveness. Finally, we empirically validated the biological implications of a critical gene, KYNU, through assays in LUAD cell lines.ResultsWe identified two DR clusters and there were great differences in overall survival (OS) and tumor microenvironment. We selected the "Least Absolute Shrinkage and Selection Operator (LASSO) + Random Survival Forest (RFS)" algorithm to develop a DS based on the average C-index across different cohorts. Our model effectively stratified LUAD patients into high- and low-DS subgroups, with this latter demonstrating superior OS, a reduced mutational landscape, enhanced immune status, and increased sensitivity to immunotherapy. Notably, the predictive accuracy of DS outperformed the published LUAD signature and clinical features. Finally, we validated the DS expression using clinical samples and found that inhibiting KYNU suppressed LUAD cells proliferation, invasiveness, and migration in vitro.ConclusionsThe DR-based scoring system that we developed enabled accurate prognostic stratification of LUAD patients and provides important insights into the molecular mechanisms and treatment strategies for LUAD.
引用
收藏
页数:20
相关论文
共 50 条
  • [31] Development and validation of a disulfidptosis-related prognostic model for colorectal cancer using multi-omics analysis
    Shi, Lei
    Wang, Huimei
    Sun, Yongxiao
    Xu, Na
    Pei, Aiyue
    Zhang, Nan
    DISCOVER ONCOLOGY, 2025, 16 (01)
  • [32] Identification of prognostic risk score of disulfidptosis-related genes and molecular subtypes in glioma
    Jiang, Qian
    Ling, Guo-Yuan
    Yan, Jun
    Tan, Ju-Yuan
    Nong, Ren-Bao
    Li, Jian-Wen
    Deng, Teng
    Mo, Li-Gen
    Huang, Qian-Rong
    BIOCHEMISTRY AND BIOPHYSICS REPORTS, 2024, 37
  • [33] A bioinformatics approach to identify a disulfidptosis-related gene signature for prognostic implication in colon adenocarcinoma
    Hu, Gunchu
    Yao, Hongliang
    Wei, Zuxing
    Li, Linye
    Yu, Zhuowen
    Li, Jian
    Luo, Xiong
    Guo, Zhushu
    SCIENTIFIC REPORTS, 2023, 13 (01):
  • [34] Integrating bioinformatics and experimental validation to unveil disulfidptosis-related lncRNAs as prognostic biomarker and therapeutic target in hepatocellular carcinoma
    Lixia Xu
    Shu Chen
    Qiaoqiao Li
    Xinyi Chen
    Yuan Xu
    Yongjian Zhou
    Juan Li
    Zhixian Guo
    Jiyuan Xing
    Di Chen
    Cancer Cell International, 24
  • [35] Integrating bioinformatics and experimental validation to unveil disulfidptosis-related lncRNAs as prognostic biomarker and therapeutic target in hepatocellular carcinoma
    Xu, Lixia
    Chen, Shu
    Li, Qiaoqiao
    Chen, Xinyi
    Xu, Yuan
    Zhou, Yongjian
    Li, Juan
    Guo, Zhixian
    Xing, Jiyuan
    Chen, Di
    CANCER CELL INTERNATIONAL, 2024, 24 (01)
  • [36] Pan-cancer Analysis of the Disulfidptosis-related Gene NCKAP1 and Its Prognostic Value for Lung Adenocarcinoma
    Zhu, Ankang
    Zong, Yan
    Wei, Shuai
    Li, Yinuo
    Fan, Yan
    Liu, Shaodong
    Gao, Xingcai
    JOURNAL OF CANCER, 2023, 14 (17): : 3351 - 3367
  • [37] Identifying and assessing a prognostic model based on disulfidptosis-related genes: implications for immune microenvironment and tumor biology in lung adenocarcinoma
    Wang, Jin
    Liu, Kaifan
    Li, Jiawen
    Zhang, Hailong
    Gong, Xian
    Song, Xiangrong
    Wei, Meidan
    Hu, Yaoyu
    Li, Jianxiang
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [38] Characterization and Prognosis of Biological Microenvironment in Lung Adenocarcinoma through a Disulfidptosis-Related lncRNAs Signature
    Yang, Zhuo
    Cao, Shenglan
    Wang, Fangli
    Du, Kangming
    Hu, Fang
    GENETICS RESEARCH, 2023, 2023
  • [39] A machine learning model and identification of immune infiltration for chronic obstructive pulmonary disease based on disulfidptosis-related genes
    Li, Sijun
    Zhu, Qingdong
    Huang, Aichun
    Lan, Yanqun
    Wei, Xiaoying
    He, Huawei
    Meng, Xiayan
    Li, Weiwen
    Lin, Yanrong
    Yang, Shixiong
    BMC MEDICAL GENOMICS, 2025, 18 (01)
  • [40] Construction of lncRNA prognostic model related to disulfidptosis in lung adenocarcinoma
    Zhang, Liming
    Wang, Shaoqiang
    Wang, Lina
    HELIYON, 2024, 10 (15)